Overview

PIE II: Pharmacological Intervention in the Elderly II

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).
Phase:
Phase 3
Details
Lead Sponsor:
Wake Forest School of Medicine
Wake Forest University
Collaborator:
National Institute on Aging (NIA)
Treatments:
Spironolactone